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The brain is remarkable in its dependence on the blood for
essentially two energy substrates, i.e., glucose and oxygen.
To maintain the brain’s high rate of aerobic metabolism,
transport of glucose into the brain occurs through regionally
selective, bidirectional, facilitated transport (Lund-Andersen
1979; Pardridge 1983; Bradbury 1993). The brain micro-
environment is isolated from the plasma by the blood–brain
barrier (BBB) formed by tight junctions between vascular
endothelial cells, where tightness excludes free diffusion
of polar, hydrophilic molecules such as glucose resulting in a
constant and signiﬁcant glucose concentration gradient from
blood to brain, i.e., approximately 5–1 [(Lund-Andersen
1979) and references therein; (Gruetter et al. 1998) and
references therein; (Barros et al. 2007)]. Glucose is trans-
ported into brain by the major high afﬁnity glucose
transporter isoform GLUT1 (Pardridge et al. 1990), distrib-
uted between the lumenal and ablumenal membranes of the
capillary endothelial cells that comprise the BBB in vivo
(Carruthers 1990).
Increases of both GLUT1 synthesis and luminal GLUT1
mediate enhanced glucose transport across the BBB into rat
brain in hypoglycemia (Simpson et al. 2007). The integrity
of the BBB for glucose transport is therefore expected to
profoundly impact the concentration of glucose in the brain
microenvironment [Gruetter et al. (1998) and references
therein] and in brain cells that use glucose either as a
signaling molecule or energy substrate for phosphorylation
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Abstract
Specialized glucosensing neurons are present in the hypo-
thalamus, some of which neighbor the median eminence,
where the blood–brain barrier has been reported leaky. A
leaky blood–brain barrier implies high tissue glucose levels
and obviates a role for endothelial glucose transporters in the
control of hypothalamic glucose concentration, important in
understanding the mechanisms of glucose sensing We
therefore addressed the question of blood–brain barrier
integrity at the hypothalamus for glucose transport by exam-
ining the brain tissue-to-plasma glucose ratio in the hypo-
thalamus relative to other brain regions. We also examined
glycogenolysis in hypothalamus because its occurrence is
unlikely in the potential absence of a hypothalamus–blood
interface. Across all regions the concentration of glucose was
comparable at a given plasma glucose concentration and was
a near linear function of plasma glucose. At steady-state,
hypothalamic glucose concentration was similar to the extra-
cellular hypothalamic glucose concentration reported by
others. Hypothalamic glycogen fell at a rate of 1.5 lmol/g/h
and remained present in substantial amounts. We conclude
for the hypothalamus, a putative primary site of brain glucose
sensing that: the rate-limiting step for glucose transport into
brain cells is at the blood–hypothalamus interface, and that
glycogenolysis is consistent with a substantial blood -to-
intracellular glucose concentration gradient.
Keywords: blood–brain barrier, glucose transport, glycogen,
hypothalamus.
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and/or whose glucosensing is altered in hyper/hypoglycemia
(Mobbs et al. 2001; Levin et al. 2004; Marty et al. 2005;
Song and Routh 2005, 2006). This is particularly relevant
to the hypothalamus: two hypothalamic glucose-sensing
structures, the arcuate nucleus and the ventral medial
nucleus neighbor the hypothalamic median eminence, a
circumventricular organ that lacks a strict BBB (Fry and
Ferguson 2007). It has therefore been suggested that the
BBB at the hypothalamus is absent or leaky (Cheunsuang
et al. 2006; Mountjoy and Rutter 2007). The potential
absence of a diffusion barrier for glucose is expected to
lead to elevated hypothalamic glucose concentrations relative
to that in other brain regions. The question remains as to
what the concentration of glucose in the hypothalamus is
since it is a key parameter linking glucose transport and
metabolism (Gruetter et al. 1998; Barros et al. 2007), and
whether the brain tissue-to-plasma glucose ratio in the
hypothalamus is similar to other brain regions that have
intact barriers.
When plasma glucose levels reach approximately 2 mM in
hypoglycemia, decreases in cerebral metabolic rates of
glucose (CMRglc) have been reported to exceed those of
oxygen in the conscious rat (Ghajar et al. 1982) indicating
that the brain uses other energy substrates, one of which is
glycogen. Brain glycogen, a predominantly glial store
of glucose equivalents, is an important endogenous energy
source to maintain brain cell function when blood–brain
glucose transport becomes rate-limiting during acute hypo-
glycemia (Choi et al. 2003; Gruetter 2003). Brain glycogen
levels are sensitive to changes in tissue and plasma glucose
concentrations (Choi et al. 2003; Morgenthaler et al. 2006)
and replete to levels higher than pre-depletion levels in brain
following a single episode of hypoglycemia (Choi et al.
2003; Oz et al. 2003).
This rebound in glycogen, known to be neuroprotective
through the breakdown into mostly glucose-6-P which is
glycolyzed to pyruvate and which has been suggested to
support neuronal metabolism in hypoglycemia, most likely in
the form of lactate (Gruetter 2003), may affect glucose
sensing by specialized neurons as they also respond to lactate
(Song and Routh 2005), and this may in part explain loss
of physiological counter-regulatory defense mechanisms in
insulin-induced hypoglycemia in diabetic patients undergo-
ing intensive insulin therapy (Bolli 2003; Criego et al. 2005).
Strong evidence suggests that the hypothalamus is a key
region in the brain responsible for hypoglycemia sensing and
for triggering physiological counter-regulatory defense
mechanisms (Borg et al. 1997) and the question remains as
to how glycogen metabolism is affected in the putative
primary site of glucose sensing, the hypothalamus. The
potential absence of a BBB at the hypothalamus is expected
to lead to similar concentrations of blood and brain glucose,
i.e., glucose phosphorylation will only be limited when
plasma glucose approaches the Km of hexokinase (50 lM),
which is practically impossible and thus glycogenolysis
would be unlikely.
The present work extends our pioneering NMR spectros-
copy data of the relationship between glucose concentration
in blood and in the brain by (i) improving the spatial
resolution of the measurements; and (ii) by validating
previous NMR measurements of glucose and glycogen in
brain tissue by a biochemical method.
Therefore, the purpose of this study was: (i) to assess the
integrity of the hypothalamic–blood interface relative to
other brain regions for the transport of glucose and (ii) to
examine whether, in support of a functional hypothalamic–
blood interface, the hypothalamus exhibits glycogen
breakdown. A preliminary report of part of this work has
appeared (Poitry-Yamate et al. 2007).
Materials and methods
Animal preparation
The study was performed in accordance with Swiss Federal
guidelines for the care and use of laboratory animals and was
approved by the ethics committee. Male Sprague-Dawley rats
(Charles River, France) weighing between 250–280 g were fasted
overnight with access to water. To enable comparison between
biochemical and previous in vivo NMR studies, measurements in the
present study were obtained from hypoglycemic, euglycemic and
hyperglycemic rats following the same preparatory glycemic
procedures carried out for in vivo 1H and 13C NMR experiments
(Choi et al. 2001). Brieﬂy, three groups of animals were studied at
target plasma glucose levels: hypoglycemia (<2 mM), euglycemia
(5–10 mM) and hyperglycemia (>10 mM). All animals were
initially anesthetized with 4% isoﬂurane in a 2 : 1 mixture of
nitrous oxide and oxygen during induction. Isoﬂurane was lowered
to 2% during catheterization. Animals were artiﬁcially ventilated
with a pressure-driven ventilator. For hyperglycemia and hypogly-
cemia studies, a-chloralose was given as an 80 mg/kg bolus
followed 10 min later by infusion at a rate of 27 mg/kg/h.
Hyperglycemic animals were maintained at a level of 17 mM
plasma glucose by adjustment of glucose infusion rate.
Insulin (1 U/mL Humulin; Lilly Inc, Paris, France) was
administered to reach a target hypoglycemia condition of plasma
glucose <2 mM for 2–3 h. The duration of hypoglycemia and
hyperglycemia before blood sampling and brain ﬁxation was on
average 3 and 7 h, respectively. Because no signiﬁcant difference
was found for total brain glucose and glycogen as a function
of plasma glucose between the light anesthetics isoﬂurane and
a-chloralose (Morgenthaler et al. 2006), we elected to use only
isoﬂurane anesthesia in the euglycemic studies. Plasma glucose in
euglycemic animals was maintained between 5 and 10 mM by
adjustment of glucose infusion rate.
Microwave fixation and brain dissection
After ﬁnal blood sampling, anesthetized animals underwent focused
microwave irradiation of 4 kW at 2450 MHz for 2 s (Gerling
Applied Engineering Inc., Modesto, CA, USA). 2 s was sufﬁcient to
provide absorption of microwave energy (and hence heat generation
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and subsequent temperature rise) between superﬁcial and deep brain
regions. Decapitation was performed after microwave ﬁxation. We
have established that this approach leads to minimal agonal
metabolism as veriﬁed from the tissue lactate levels (Morgenthaler
et al. 2006). The cortical surface of the brain was then exposed,
meninges removed and ﬁve brain regions of interest were dissected
within 2 min in the following order: olfactory bulb, hypothalamus,
then coronal sections of frontal cortex, hippocampus and cerebel-
lum. Care was taken to consistently take the same region in coronal
sections and to keep tissue sample volumes similar, i.e.
<1 · 3 · 3 mm3 or  between 5–10 mg of wet weight tissue.
Biochemical measurements
Following the determination of wet weight of each freshly dissected
brain sample, the sample was immediately immersed in 250 lL of
0.03 M HCl, the contents were homogenized using an ultrasonic
homogenizer probe microtip (Bandelin, Berlin, Germany), and
immediately divided into two equal volumes, one for determination
of free glucose and the second for the determination of digested
glycogen plus free glucose.
The release of glucose from glycogen by amyloglucosidase
(10 mg/mL, Roche Applied Science, Rotkreuz, Switzerland) was
performed following the procedure described by Cruz and Dienel
(Cruz and Dienel 2002). Samples digested by amyloglucosidase
from tissue at euglycemia and hyperglycemia were diluted between
two and ﬁve-fold in water (pH 7.4) such that spectroscopic
absorbance values fell in the middle of the glucose-absorbance
calibration curve.
Tissue glucose, whether for the background or digested sample,
was assayed using Trinder’s method (Amplex Red, Invitrogen,
Basel, Switzerland) and the samples in the present study were not
frozen prior to glucose measurements. Glucose Standards, prepared
from commercially available D-glucose, were left at room temper-
ature (22C) for 3 h prior to use. This assay is based on glucose
oxidase digestion, forming H2O2 which reacts with peroxidase
substrate in the presence of horseradish peroxidase to generate
resoruﬁn. All samples, including standards, were brought to pH 7.4
using NaOH and equal volumes of samples and reaction buffer
reagent, typically 60 lL, were used. 100 lL of the ﬁnal 120 lL
solution of (sample + reaction buffer reagent) was transferred under
dim room light to a 96-well microplate and left in darkness for
30 min at room temperature before absorption measurements.
Maximum absorbance was attained at room temperature at
k = 560 nm, pH > 7, 30 min after the reagent was added. Absor-
bance as a function of D-glucose concentration was measured using
a Biotek Powerwave XS spectrophotometer (Bio-Tek Instruments,
Inc. Burlington,VT, USA).
Absorbance values of brain glucose and brain glycogen, i.e., the
difference between digested and background glucose) were
expressed in units of lmol/g wet weight using the equation:
½Glc ¼ ðVab  AÞ=B
H
; ð1Þ
where Vab is the absorbance value, A is the y-intercept; and B is
the slope from linear regression plots of absorbance as a function
of glucose concentration. H is the starting dilution factor =
(mg tissue wet weight)/(250 lL 0.03 M HCl + mg tissue wet
weight).
Determination of glucose transport kinetics
To allow comparison with previous whole-brain rat NMR
results, i.e., under similar experimental conditions and
anesthesia protocols, we measured brain glucose as a function
of plasma glucose at steady-state and express the relationship
as a linear function and report the apparent kinetic constants
(Gruetter et al. 1998; Pfeuffer et al. 2000; Choi et al. 2001;
Lei and Gruetter 2006) from the linear regression plots of
plasma glucose and tissue glucose using the expression:
Gbrain ¼ Vd
Tmax
CMRGlc
 1
 
Gplasma  Kt
Tmax
CMRGlc
þ 1 : ð2Þ
Where G is the concentration of glucose by brain region
indicated (lmol/g) or in plasma (mmol/L); Vd = 0.77 mL/g,
the physical distribution space of water in brain; Tmax is the
apparent maximum transport rate, CMRglc is the cerebral
metabolic rate of glucose utilization and Kt, the apparent
Michaelis–Menten constant. The equation was ﬁtted using
OriginPro 7.5 (OriginLab Corporation, Northampton, MA,
USA).
Results
To measure glucose and/or glycogen from small volumes
(5–10 lL) of tissue samples, we implemented an enzymatic-
absorbance based assay previously used in quantifying
hepatic glycogen (Dong et al. 2006) and plasma glucose
(Koch and Nipper 1977). This assay was inherently sensitive,
and between 0.00095 and  0.125 mM glucose, with a
precision of < 2% (Fig. 1). Omission of the Amplex Red
reagent (shown by the dotted line) to verify reaction
speciﬁcity resulted in constant absorbance.
Tissue glucose concentrations were comparable at a given
plasma glucose concentration across all brain regions,
averaging 1.6 lmol/g at euglycemia (5–10 mM plasma
glucose), 0.2 lmol/g at hypoglycemia (<2 mM plasma
glucose) and 4.0 lmol/g at hyperglycemia (10–22 mM
plasma glucose). In all ﬁve brain regions the concentration
of tissue glucose consistently increased in a nearly
linear fashion with plasma glucose concentration (Fig. 2).
Of particular interest was the 5 : 1 ratio observed at
euglycemia between glucose concentration in blood and
hypothalamus (Fig. 2). The brain/plasma glucose concentra-
tion ratio indicated for each brain region in Fig. 2 was similar
in the various brain structures and not statistically signiﬁcant
from each other.
The relationship between brain and plasma glucose
concentration was ﬁt using Eqn (2). Values of Tmax/CMRglc
varied from 2.5 ± 0.2 (hypothalamus and cortex), 1.9 ± 0.2
(cerebellum). Kt was on the order of a few mM:
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3.2 ± 0.9 mM in hippocampus and cortex; 1.5 ± 0.9 mM in
olfactory bulb, 0.1 ± 1.0 mM in cerebellum and
2.6 ± 1.1 mM in hypothalamus.
The effect of glycemia on glycogen concentration and
metabolism in the hypothalamus is shown in Table 1 and
compared with four other brain regions. After 2 h of
hypoglycemia (< 2 mM plasma) glycogen remained present
in substantial amounts in all ﬁve brain regions. Glycogen was
reduced from 4.5 to 1.6 lmol/g, equivalent to a rate of
 0.025 lmol/g/min (for hypothalamus, cortex and cerebel-
lum) and from 3.2 to 1.8, equivalent to a rate of
0.011 lmol/g/min (for olfactory bulb and hippocampus).
When plasma glucose was raised to >10 mM from
euglycemia, glycogen content increased slightly in all ﬁve
regions and reached statistical signiﬁcance in olfactory bulb
(p < 0.001, Table 1).
Fig. 1 Sensitivity, linearity and reproducibility of glucose assay using
glucose oxidase. Standards of D-glucose ranging from 0.00095 to
0.125 mM were linearly related to absorbance of resorufin at 560 nm
in the presence of reagent (n = 6 replicates). The dotted line corre-
sponds to the fit of the same glucose standards in the absence of
reagent (n = 2 replicates). Inset shows regions of non-linearity of
assay, starting from arrow.
Fig. 2 Relationship between brain and plasma glucose concentration
from anatomically and functionally distinct brain regions. Regression
lines of plots show the best-fit of the model of glucose transport (as
described in Materials and methods) to the data points measured
biochemically over an extended range of plasma glucose levels
(1.4 to 22 mM). All brain regions showed near linearity. The mean
values of the slope ± SD by brain region are indicated. Linear
regression plots were then used to determine the kinetic parameters,
Kt and Tmax/CMRglc. > 40 independent glucose measurements were
performed per brain region except for cerebellum (n = 19).
Table 1 Glycogen content by brain region and plasma glucose con-
centration
Hypoglycemia
<2 mM
Euglycemia
5–8 mM
Hyperglycemia
>10 mM
Hypothalamus 1.9 ± 0.8 (8)** 4.4 ± 1.0 (14) 5.5 ± 1.6 (7)
Cortex 0.9 ± 1.2 (5)* 4.0 ± 1.4 (13) 5.1 ± 1.9 (9)
Olfactory bulb 1.7 ± 1.0 (8) 2.9 ± 0.8 (16) 5.1 ± 1.4 (8)**
Hippocampus 1.8 ± 1.5 (7) 3.4 ± 1.1 (13) 3.4 ± 1.9 (8)
Cerebellum 1.5 ± 1.3 (5)* 4.4 ± 1.6 (5) 6.1 ± 1.9(4)
Values are mean lmol/g ± SD based on (n measurements). Glycogen
content in hypoglycemia and hyperglycemia was compared with that in
euglycemia using two-way ANOVA following the Bonferroni post-tests.
*Indicates a significant difference for p < 0.01 and ** for p < 0.001.
 2009 The Authors
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Levels of tissue glycogen and glucose as a function of
plasma glucose for the hypothalamus and cortex are given in
Table 1 and Fig. 2, and show that in both regions glycogen
exceeds glucose levels.
Discussion
We implemented a highly sensitive and reproducible enzyme
and absorbance-based assay using glucose oxidase (Fig. 1).
In conjunction with uniform microwave ﬁxation of super-
ﬁcial and deep brain regions, the enzymatic assay allowed
the use of small, 10 lL volumes of tissue with minimal
partial volume effects. It is important to note that beyond
125 lM glucose, the absorption of resoruﬁn was no longer
linear (Fig. 1, inset), necessitating care to choose appropriate
sample dilutions. We went on to use this biochemical assay
to determine whether the brain tissue-to-plasma glucose ratio
was similar in the hypothalamus compared with other brain
regions of a-chloralose anesthetized rats, and also at
hypoglycemia and hyperglycemia.
The linearity shown in Fig. 2 by brain region was in
excellent agreement with that previously measured for whole
brain and lends support to the notion that the whole brain
represents the weighted average of the levels of its compo-
nent parts (Gruetter et al. 1996, 1998; Choi et al. 2001,
2002; de Graaf et al. 2001; Lei and Gruetter 2006).
The similar brain tissue-to-plasma glucose ratio between
hypothalamus and the other anatomically distinct brain
regions (Fig. 2) suggests similar glucose transport kinetics.
Implicit in all aforementioned glucose transport models is
the assumption that: (i) the concentration gradient of glucose
is primarily at the entry of glucose into the brain, i.e., the
endothelial cells or astrocytic endfoot processes, and (ii) that
glucose is uniformly distributed in the brain aqueous phase
beyond the BBB. Indeed, a 5 : 1 ratio of plasma to tissue
glucose concentration at euglycemia across all brain regions,
including the hypothalamus (Fig. 2) supports the presence
of a signiﬁcant glucose concentration gradient from blood to
brain (Gruetter et al. 1992, 1996, 1998). Total tissue glucose
concentrations, which represent extracellular and intracellu-
lar glucose levels, have been indirectly assessed from the
equilibrium brain/plasma distribution ratio of 3-0-methyl-
D-glucose (Gjedde and Diemer 1983; Namba et al. 1987;
Dienel et al. 1991; Nakanishi et al. 1996) implying a
relative regional uniformity of brain glucose concentrations.
However, 3-0-methyglucose differences between the
extracellular space and intracellular space have not been
established.
We have previously shown that deep anesthesia increases
brain glucose content at a given plasma glucose concentra-
tion (Choi et al. 2002) and the anesthesia in the present study
might have led to an overestimated hypothalamic glucose
concentration. However, the presence of a signiﬁcant blood/
brain glucose concentration gradient in anesthetized brain
only underlines the presence of a signiﬁcant diffusion barrier
for glucose entry into the hypothalamus.
When comparing the tissue glucose measurements with
extracellular, i.e., interstitial glucose measurements in hypo-
thalamus (Fig. 3) the two were on the same order of
magnitude and clearly lower than the plasma glucose
concentration, with the implication that at steady-state,
glucose concentrations are similar in the intracellular and
extracellular space. This observation strongly suggests a
structural and functional transport barrier for glucose entry
across the hypothalamus–blood interface. Even if deeper
anesthesia was used in some of the extracellular measure-
ments used for Fig. 3, the main conclusion is unaffected by
the speciﬁc degree of anesthesia, since deeper anesthesia
tends to reduce the concentration gradient (Choi et al. 2002).
In addition to the BBB, other potential routes of entry of
glucose into the hypothalamus are indirectly via the CSF
(Broadwell et al. 1983) or via transport-independent mech-
anisms (Faouzi et al. 2007). A signiﬁcant CSF-to-median
eminence exchange that would elevate the concentration
of glucose preferentially in hypothalamus is, however,
unlikely: immunohistochemical evidence shows low to
absent expression of GLUT1 in hypothalamic b2-tanycytes
that participate in forming an efﬁcient barrier system between
the median eminence and CSF (Peruzzo et al. 2000; Garcia
et al. 2001) and inﬂux is expected to be minimal because of a
103-fold lower circumventricular organ surface area relative
to that of the BBB (Kastin and Pan 2006).
The relationship established between increased whole
brain glucose concentration and reported changes of endo-
Fig. 3 Comparison of tissue and interstitial glucose concentration for
hypothalamus as a function of plasma glucose. The concentrations of
hypothalamic glucose (open squares) were those determined in the
present study (Fig. 2) at plasma glucose concentrations (in mM) of
1.5 ± 0.03; 7.9 ± 0.1; 9.8 ± 0.1; n = 5 per point. Interstitial glucose
concentrations: zero-net flux in unrestrained rats (closed squares)
from (de Vries et al. 2003); and implanted glucose microelectrodes in
pentobarbital-anesthetized rats (closed triangles) from (Silver and
Erecinska 1994). R2 refers to hypothalamic tissue glucose.
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thelial GLUT1 protein in sustained hypoglycemia suggests
that a normal glucose environment in brain can be created as
a consequence of increased GLUT1 expression and
up-regulation and/or sequestration of GLUT1 protein at the
BBB mediated by ambient glucose concentration (Lei and
Gruetter 2006). Such a mechanism is a likely alternative
explanation to the observed hypoglycemia unawareness in
patients undergoing intensive insulin treatment of diabetes,
although sequestration of GLUT1 at the BBB might also
allow for acute regulation of glucose transport (Barros et al.
2005). The similar values obtained of kinetic constants for
glucose transport at steady-state between whole brain
measurements and anatomically and functionally distinct
brain regions suggests that such a blunting of normal glucose
sensing by the brain may speciﬁcally involve increased
GLUT1 expression and up-regulation and/or sequestration of
GLUT1 protein at the BBB at the hypothalamus, a key
glucose sensing region for triggering hypoglycemic counter-
regulatory defense mechanisms (Borg et al. 1997).
Under euglycemic conditions, the concentration of glyco-
gen in all ﬁve regions of the brain was higher than that of the
corresponding brain glucose (cf. Fig. 2 and Table 1)
suggesting that the brain synthesizes and stores glycogen
as a likely reserve supply of energy (Gruetter 2003). Indeed,
the ﬁnding that 2 h of severe, acute hypoglycemia did not
completely deplete brain glycogen in any brain region
studied (Table 1) demonstrates that functionally distinct
areas of the brain may survive extended periods of
hypoglycemia through glycogenolysis. These observations
extend the importance of glycogen as being neuroprotective
when BBB glucose transport becomes rate-limiting for
glucose metabolism (Choi et al. 2003; Lei and Gruetter
2006; Morgenthaler et al. 2006; Suh et al. 2007). At a
plasma glucose concentration of 1.5 mM attained during
hypoglycemia in the present study, we estimated a 10%
glucose deﬁcit in hypothalamus, cortex and hippocampus.
Therefore, glycogenolysis accounts for a substantial fraction
of the estimated 10% glucose supply deﬁcit for all reported
and estimated glucose metabolic rates (Sokoloff et al. 1977),
as previously reported for whole rat brain (Choi et al. 2003).
Similar net glycogen utilization rates in cortex and
hippocampus have been reported in unrestrained rats (Herzog
et al. 2008), after taking into account differences in the
severity and duration of hypoglycemia (1.9 vs 1.5 mM; and 3
vs. 2 h). However, in that study, the reported glycogenolytic
rate was 50% lower than ours in the hypothalamus and this
difference cannot be explained by differences in the
measured, control glycogen concentrations, which were
similar.
In previous brain studies, hyperglycemia was shown to
increase glycogen content (Nelson et al. 1968; Swanson
et al. 1989; Morgenthaler et al. 2006). Here, a similar trend
was observed (Table 1) but not statistically signiﬁcant for all
brain regions. Future studies are needed to establish glycogen
levels and brain tissue-to-plasma glucose ratios by brain
region in hyperglycemia, which would suggest that tissue
glucose itself may affect glycogen levels.
In conclusion, biochemical evidence has been presented in
support of a functional hypothalamus–blood interface for the
transport of glucose. We speculate that in such an environ-
ment, specialized glucosensing neurons in the hypothalamus
may effectively monitor and respond to the availability of
glucose [for reviews, see Routh et al. (2004); Marty et al.
(2007); McCrimmon (2008)]. In this connection, and beyond
the BBB, accumulating evidence shows that neuron function
is ﬁnely modulated by surrounding glia, such that these two
major cell types interact synergistically (Poitry-Yamate et al.
1995), inviting the question as to the extent the process of
glucose sensing is altered by the function of glial cells and
glial glycogen.
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